ETF Holdings Breakdown of ATRC

Stock NameAtriCure Inc
TickerATRC(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS04963C2098

News associated with ATRC

Dimensional Fund Advisors LP Raises Position in AtriCure, Inc. (NASDAQ:ATRC)
Dimensional Fund Advisors LP increased its stake in shares of AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 24.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 700,212 shares of the medical device company’s stock after acquiring an additional 136,015 shares during the quarter. Dimensional Fund Advisors LP’s holdings in AtriCure were worth $21,398,000 […] - 2025-05-08 07:45:00
Barclays PLC Has $2.64 Million Holdings in AtriCure, Inc. (NASDAQ:ATRC)
Barclays PLC trimmed its holdings in AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 33.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 86,541 shares of the medical device company’s stock after selling 42,724 shares during the quarter. Barclays PLC’s holdings in AtriCure were worth […] - 2025-05-01 08:14:58
AtriCure (NASDAQ:ATRC) Trading Up 4.9% After Better-Than-Expected Earnings
AtriCure, Inc. (NASDAQ:ATRC – Get Free Report)’s share price traded up 4.9% on Tuesday following a stronger than expected earnings report. The company traded as high as $35.19 and last traded at $35.31. 373,568 shares were traded during mid-day trading, a decline of 43% from the average session volume of 654,896 shares. The stock had […] - 2025-05-01 05:40:58
Envestnet Asset Management Inc. Cuts Position in AtriCure, Inc. (NASDAQ:ATRC)
Envestnet Asset Management Inc. decreased its stake in AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,086 shares of the medical device company’s stock after selling 2,104 shares during the period. Envestnet Asset Management […] - 2025-04-30 07:42:56
Raymond James Financial Inc. Acquires Shares of 121,591 AtriCure, Inc. (NASDAQ:ATRC)
Raymond James Financial Inc. acquired a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 121,591 shares of the medical device company’s stock, valued at approximately $3,716,000. Several other hedge […] - 2025-04-27 09:26:45
AtriCure (NASDAQ:ATRC) and KORU Medical Systems (NASDAQ:KRMD) Financial Survey
AtriCure (NASDAQ:ATRC – Get Free Report) and KORU Medical Systems (NASDAQ:KRMD – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends. Valuation and Earnings This table compares AtriCure […] - 2025-04-22 05:50:55
Townsquare Capital LLC Decreases Stake in AtriCure, Inc. (NASDAQ:ATRC)
Townsquare Capital LLC decreased its holdings in AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 4.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 16,138 shares of the medical device company’s stock after selling 789 shares during the period. Townsquare Capital LLC’s holdings in AtriCure were worth $493,000 […] - 2025-04-21 08:26:42
JPMorgan Chase & Co. Buys 110,039 Shares of AtriCure, Inc. (NASDAQ:ATRC)
JPMorgan Chase & Co. increased its stake in shares of AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 43.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 365,183 shares of the medical device company’s stock after acquiring an additional 110,039 shares during the quarter. JPMorgan Chase & Co.’s holdings in AtriCure were worth $11,160,000 […] - 2025-04-14 07:39:04
Corebridge Financial Inc. Reduces Holdings in AtriCure, Inc. (NASDAQ:ATRC)
Corebridge Financial Inc. lowered its stake in shares of AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 7.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 23,535 shares of the medical device company’s stock after selling 1,776 shares during the quarter. Corebridge Financial Inc.’s […] - 2025-04-07 07:32:51
Analysts Set AtriCure, Inc. (NASDAQ:ATRC) Target Price at $51.56
Shares of AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) have earned an average recommendation of “Buy” from the nine analysts that are currently covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have issued ratings on the stock in the […] - 2025-03-28 06:56:46
Needham & Company LLC Reaffirms “Buy” Rating for AtriCure (NASDAQ:ATRC)
Needham & Company LLC reaffirmed their buy rating on shares of AtriCure (NASDAQ:ATRC – Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a $51.00 price target on the medical device company’s stock. Several other analysts also recently commented on ATRC. JMP Securities reaffirmed a “market outperform” rating and […] - 2025-03-24 06:34:46
AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd lessened its position in AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 31.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,997 shares of the medical device company’s stock after selling 6,887 shares during the period. […] - 2025-03-03 08:28:58
Venturi Wealth Management LLC Boosts Position in AtriCure, Inc. (NASDAQ:ATRC)
Venturi Wealth Management LLC increased its stake in AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 1,337.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,257 shares of the medical device company’s stock after buying an additional 2,100 shares during the period. Venturi Wealth […] - 2025-02-25 09:01:02
JPMorgan Chase & Co. Issues Positive Forecast for AtriCure (NASDAQ:ATRC) Stock Price
AtriCure (NASDAQ:ATRC – Free Report) had its price target boosted by JPMorgan Chase & Co. from $40.00 to $51.00 in a research report released on Tuesday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical device company’s stock. A number of other equities analysts have also recently issued reports on […] - 2025-02-12 08:32:59
AtriCure, Inc. (NASDAQ:ATRC) Receives $43.38 Average Price Target from Analysts
AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) has earned an average rating of “Buy” from the eight research firms that are covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have covered the stock in the last year […] - 2025-02-06 07:14:56

ATRC institutional holdings

The following institutional investment holdings of ATRC have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 34,120USD 1,063,862
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 47,640USD 1,485,415
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 62,024USD 1,933,908
2025-05-08 IE00BMX0DF60 (iShares US Medical Devices UCITS ETF) 9,025USD 281,400
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 1,551USD 48,360
Total =154,360 USD 4,812,945
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.